Abstract：
Intestinal fungi play an important role in the health-disease process. We observed that in liver diseases, fungal infections lead to high mortality. In this review, we were able to gather and evaluate the available scientific evidence on intestinal mycobiota and liver diseases. We searched PubMed and Embase, using a combination of several entry terms. Only studies in adults ≥ 18 years old with liver disease and published after 2010 were included. We observed that individuals with liver disease have an altered intestinal mycobioma, which accompanies the progression of these diseases. In cirrhotic patients, there are a high number of Candida sp. strains, especially Candida albicans. In early chronic liver disease, there is an increase in alpha diversity at the expense of Candida sp. and conversely, in advanced liver disease, there is a negative correlation between alpha diversity and model for end-stage liver disease score. On the other hand, patients with non-alcoholic fatty liver disease demonstrate greater diversity compared to controls. Our study concluded that the evidence on the subject is sparse, with few studies and a lack of standardization of outcome measures and reporting, and it was not possible to perform a meta-analysis capable of synthesizing relevant parameters of the human mycobiotic profile. However, certain fungal genera such as Candida play an important role in the context of liver disease and that adults with liver disease have a distinct gut mycobiotic profile from healthy controls.
In people with end-stage liver disease, there is a high mortality from fungal infections. In this context, the genus Candida plays an important role in the context of liver disease, and adults with liver disease have a distinct gut mycobiota profile from healthy controls.
In people with end-stage liver disease, there is a high mortality from fungal infections. In this context, the genus Candida plays an important role in the context of liver disease, and adults with liver disease have a distinct gut mycobiota profile from healthy controls.
摘要：
肠道真菌在健康疾病过程中起着重要作用。我们观察到在肝脏疾病中，真菌感染导致高死亡率。在这篇综述中，我们能够收集和评估有关肠道真菌群和肝脏疾病的现有科学证据。我们搜索了PubMed和Embase,使用几个条目术语的组合。仅纳入2010年后发表的≥18岁成人肝病研究。我们观察到患有肝病的个体具有改变的肠道分枝杆菌瘤，伴随着这些疾病的发展。在肝硬化患者中，有大量的念珠菌sp。菌株，尤其是白色念珠菌.在早期慢性肝病中，α多样性的增加是以假丝酵母为代价的。反过来,在晚期肝病中，α多样性与MELD评分呈负相关。另一方面,与对照组相比,非酒精性脂肪性肝病患者表现出更大的多样性.我们的研究得出结论，关于这个主题的证据很少，由于研究很少，结果测量和报告缺乏标准化，并且无法进行能够合成人类分枝杆菌谱相关参数的荟萃分析。然而,某些真菌属如念珠菌属在肝病中发挥重要作用,患有肝病的成年人与健康对照者有不同的肠道真菌谱.
在终末期肝病患者中，真菌感染的死亡率很高。在这种情况下，念珠菌属在肝脏疾病中起着重要作用，与健康对照组相比，患有肝病的成年人具有不同的肠道分枝杆菌谱。
在终末期肝病患者中，真菌感染的死亡率很高。在这种情况下，念珠菌属在肝脏疾病中起着重要作用，与健康对照组相比，患有肝病的成年人具有不同的肠道分枝杆菌谱。
